SAN FRANCISCO and SUZHOU, China, May 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other...
Hence then, the article about innovent announces oral presentation of full phase 2 clinical data for efdamrofusp alfa ibi302 first in class anti vegf complement bispecific fusion protein at arvo 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 )
Also on site :
- Lauren Chapin, the Youngest Kid on ‘Father Knows Best,’ Dies at 80
- Aldi's is Selling a Versatile $6 Meal Prep Essential Home Cooks Will Love
- S.S. Rajamouli Unveils Motion Capture Facility at Nagarjuna’s Annapurna Studios; Key ‘Varanasi’ Sequences Shot at Lab (EXCLUSIVE)